AX-2026-042457 · Afamelanotide · Homopeptide lot HOMO-2509-K4706

Section 1

Results

Measured against the index acceptance specification for the melanocortin-receptor peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 30 min gradient, 214 nm	99.21	% area	≥ 98.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.79	% area	≤ 2.0	PASS
Largest single impurity	RP-HPLC — des-acetyl (−42 Da)	0.35	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	1645.8474	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	1645.8512	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+2.3	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	91.37	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	90.65	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	9.89	mg	10 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	8.965	mg	10 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	89.6	%	90.0 – 110.0	FAIL
Water content	Karl Fischer, coulometric, duplicate	4.94	%	≤ 8.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	2.73	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.96	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.54	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Faint haze, clearing on standing	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.49	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 30 min gradient	10.79	min	10.86 ± 0.30 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.12	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	71,349	—	≥ 20,000	PASS
Resolution to nearest impurity	vs oxidised Trp (+16 Da)	2.29	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 30 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 71,349, and skew follows the reported asymmetry factor of 1.12. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.35 % impurity against a 99.21 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Afamelanotide — main peak	10.79	4,821,914	99.21	—
2	des-acetyl (−42 Da)	10.27	17,011	0.35	-42.011
3	native α-MSH (−32 Da)	10.13	14,095	0.29	-32.037
4	Met sulfoxide (+16 Da)	10.35	3,888	0.08	+15.995
5	oxidised Trp (+16 Da)	10.41	3,402	0.07	+15.995
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 1645.8474 Da, computed from C78H111N21O19. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 1645.8512 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
4+	412.4691	412.4701	0.0010	8.4
3+	549.6231	549.6243	0.0012	52.0
2+	823.9310	823.9329	0.0019	100.0
1+	1646.8547	1646.8585	0.0038	51.8

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	4.94
Counter-ion (acetate)	ion chromatography	2.73
Residual solvent + inorganic residue	estimated	0.96
Total peptide content	by difference	91.37
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.5	99.21	divergence +0.29 pp vs batch median
Total impurities (% area)	0.50	0.79
Largest single impurity (% area)	0.21	0.35
Water (%)	3.1	4.94
Counter-ion (%)	not stated	2.73
Peptide content (%w/w)	not stated	91.37
Endotoxin (EU/mg)	not stated	0.54
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Buyer-sourced
Evidentiary weight: Strongest available evidence in this index.
Chain of custody: Retail purchase → submitter (−20 °C, 14 d) → laboratory (courier, dry ice, 12 d) → assay.
Assay date: 02 Feb 2026
Submitted to the index: 24 Feb 2026
Laboratory: Janoshik Analytical, Ostrava, Czechia
Method basis: 30 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations 4

Signed technical comments from index contributors. Not a discussion forum — annotations question or contextualise the result, and the data team replies where a reply is warranted.

round_numbers24 Feb 2026

The declared figure for HOMO-2509-K4706 and the independent median differ by less than the inter-lab limits of agreement. That is the comparison that matters and the rounding does not change it.

one_directional24 Feb 2026

Direction is the thing to watch, not roundness. Rounded declarations in this index sit above and below the independent median at close to equal rates, which is what scatter looks like.

shipping_temp24 Feb 2026

The custody block above records the shipping conditions this vial actually experienced, which is the condition an ordinary buyer's vial experiences too. That representativeness is the point.

desiccant_note24 Feb 2026

The packaging as received is part of the evidence on a retail purchase. Whether a desiccant was in the box is a fact about ordinary shipments, not about sample shipments.

Section 7

Related records

Same batch — lot HOMO-2509-K4706 n=1

This is the only report on this lot. One report is not a batch characterisation.

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Afamelanotide records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043233	SGN	SGN-2602-Y9306	Janoshik	2026-Q3	98.76	4.02	92.2	Buyer-sourced	1	MARGINAL
AX-2026-043234	SGN	SGN-2602-Y9306	Kestrel	2026-Q3	99.93	4.16	—	Buyer-sourced	0	PASS
AX-2026-042342	TFC	TFC-2601-L2937	VendorInvestigate	2026-Q2	99.06	3.47	—	Laboratory-retained	0	PASS
AX-2026-042476	Homopeptide	HOMO-2511-V4580	Nordanalyt	2026-Q1	99.38	5.41	—	Buyer-sourced	1	FAIL
AX-2026-041858	GSP	GSP-2508-U3747	Janoshik	2025-Q4	99.55	5.84	97.0	Buyer-sourced	0	PASS
AX-2025-020677	SGN	SGN-2510-R8306	VendorInvestigate	2025-Q4	98.01	4.92	97.5	Buyer-sourced	1	FAIL
AX-2025-020681	SGN	SGN-2510-R8306	PeptideMeter	2025-Q4	98.42	4.76	94.3	Buyer-sourced	0	PASS
AX-2025-020674	SGN	SGN-2510-R8306	Janoshik	2025-Q4	98.22	5.36	—	Buyer-sourced	0	PASS

Other recent Homopeptide records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Result
AX-2026-042437	Retatrutide	HOMO-2605-V4718	Nordanalyt	2026-Q3	98.68	3.67	102.8	Buyer-sourced	PASS
AX-2026-042424	Semaglutide	HOMO-2604-X3806	PeptideMeter	2026-Q3	98.85	4.87	92.0	Buyer-sourced	PASS
AX-2026-042503	IGF-1 LR3	HOMO-2607-P5131	Janoshik	2026-Q3	99.36	5.99	—	Buyer-sourced	PASS
AX-2026-042492	SS-31 (Elamipretide)	HOMO-2604-D5484	Medutest	2026-Q3	99.93	2.40	—	Buyer-sourced	PASS
AX-2026-042491	SS-31 (Elamipretide)	HOMO-2604-D5484	Kestrel	2026-Q3	99.93	3.24	—	Supplier-supplied	PASS
AX-2026-042473	LL-37	HOMO-2602-G5165	Janoshik	2026-Q3	99.01	5.00	—	Buyer-sourced	PASS
AX-2026-042441	Retatrutide	HOMO-2605-V4718	Medutest	2026-Q3	98.93	4.22	—	Buyer-sourced	PASS
AX-2026-042474	LL-37	HOMO-2602-G5165	Janoshik	2026-Q3	99.18	5.44	—	Buyer-sourced	PASS